Robot-assisted surgery for kidney tumors without sutures
Official title: Zero Ischemia Robot-Assisted Microwave Ablation Assisted Suture-less Enucleation of Renal Cell Carcinoma With T1 Stage: A Randomized Clinical Trial
Run by RenJi Hospital · NCT06715878 · Data updated 2026-11-12
This study is testing a new robot-assisted surgery method for kidney tumors that doesn’t use stitches to see if it helps patients keep more of their kidney function compared to standard surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 15 Years to 80 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | March 1, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | December 10, 2024 |
| Trial ID | NCT06715878 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with sporadic, unilateral, newly diagnosed T1 renal cell carcinoma who are scheduled for robot-assisted laparoscopic nephron-sparing surgery.
✕Probably not a fit
Patients over 80 years old or those with other renal diseases that could affect kidney function may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates a novel approach to treating T1 stage renal cell carcinoma (RCC) using zero ischemia robot-assisted microwave ablation combined with suture-less tumor enucleation. The study aims to enhance renal function preservation compared to traditional laparoscopic methods by utilizing real-time contrast-enhanced ultrasonography to monitor tumor ablation during surgery. By minimizing bleeding and simplifying the surgical process, this technique seeks to improve outcomes for patients undergoing nephron-sparing surgery. The trial will involve patients with newly diagnosed unilateral T1 RCC who meet specific eligibility criteria.
Why it matters
Potential benefit: If successful, this approach could lead to better preservation of kidney function in patients undergoing surgery for renal tumors.
How similar studies have gone: Previous studies have shown success with similar zero ischemia techniques in laparoscopic surgery, but this specific robotic approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients with sporadic, unilateral, newly diagnosed T1 presumed renal cell carcinoma 2. patients scheduled for robot-assisted laparoscopic nephron sparing surgery 3. patients with normal contralateral renal function (differential renal function of \>40% as determined by radionuclide scintigraphy) 4. patients agreeable to participate in this long-term follow-up study Exclusion Criteria: 1. patients' age \>80 years 2. patients with other renal diseases (including kidney stone, glomerular nephritis, etc.)which might affect the renal function of the operative kidney 3. patients not able to tolerate the robot-assisted laparoscopic procedure 4. patients with previous renal surgery or history of any inflammatory conditions of the operative kidney 5. patients with the renal tumor involving urinary collecting system or distance from the tumor edge to the collecting system ≤ 4 mm
Where it's running
-
Ethics Committee of Shanghai Renji Hospital
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jiwei Huang, PhD.
- Email: huangjiwei@renji.com
- Phone: 02168383204
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
-
Contrast-Enhanced Super-Resolution (CESR) Ultrasound for Imaging Breast, Liver, and Kidney Lesions
The team will try a new contrast-enhanced super-resolution ultrasound (CESR) to see if it images known lesions in the breast, liver, or kidney more clearly in adults scheduled for biopsy and in healthy volunteers.
-
CD70-targeted immunoPET Imaging of Kidney Cancer
This study is testing a new imaging technique that uses a special marker to help doctors see kidney cancer more clearly.
-
Using vorolanib for treating advanced kidney cancer
This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.
-
Using a digital tool to improve kidney surgery planning
This study is testing a new digital tool to see if it helps doctors plan kidney surgery better for patients with localized kidney cancer compared to just using regular CT scans.
-
Evaluating HTL0039732 for Advanced Solid Tumours
This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.